Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
The first selling of Tranche 1 shares by Lanstead will happen after 17th February for payment to Nuformix after 17th March.
I believe there will be positive news releases before then to bolster the sp.
I understand your frustration FFS - I am also frustrated but also a lot more optimistic than I was a few months ago - we have really positive results for both NXP004 and NXP002 now - so good in fact that they are undertaking extra research to add to and strengthen our patent IP even further in order to further increase the licensing value achieved.
With the best part of £1m in cash I hoped that such a funding would not happen for some time - but it seems that, based upon the excellent results achieved, they are going all out on all fronts: on the NXP004 additional patent data, the NXP002 preclinical studies and business development for both NXP004 and NXP002 licensing.
A lot of success has been achieved in the last 6 months - we just need the sp to reflect that success.
Just my take on our situation.
Good luck
Allenby say 'We adjust our projected March 2022 cash to about £940k.'
Then you have to add the £1.65m nominal proceeds from the Lanstead subscription (assuming the sp is an overall average of 2p)
So that gives Nuformix £2.6m.
If they get an overall average of 2.5p then they will have funding of £3m.
So hopefully we should now have enough to get NXP002 phase 1 ready and undertake the business development to license it out.
AR appears to be very a cautious character and I do not think he would have entered into this agreement if he did not think they had sufficient good news coming along to raise the sp at least to the 2p level.
I think the new CEO is imminent and I also believe NXP004 licensing will push the sp up over the next few months.
GLA
FFS - Tranche 1 share selling not for couple of months
Taken from the subscription RNS
‘The monthly settlement amounts for the First Sharing Agreement are structured to commence approximately three months following Admission of the First Subscription Shares.’
So we have a couple of months for the share price to hopefully rise and then from about 17th February until 17th March will be the share price qualifying period for the first monies from Lanstead, which will be paid around 17th March.
OR am I reading it wrong?
Agree with your comments Soup.
Seems a very lazy re-hash of earlier report.
As you say effectively excludes NXP004 - and seems to totally ignore fact that they are now talking about NXP004 licensing with potential licensees.
So we have a couple of months for the share price to hopefully rise and then from about 17th February until 17th March will be the share price qualifying period for the first monies from Lanstead, which will be paid around 17th March.
AR seems very positive about NFX prospects.
GLA
‘The monthly settlement amounts for the First Sharing Agreement are structured to commence approximately three months following Admission of the First Subscription Shares.’
So it will be mid-March 2022 before we get a first glimpse of what this deal means and is obviously dependent upon the sp at that time.
Hopefully business development progress with NXP004 will be evident by then to bolster the sp.
I believe the NXP004 originator will want NXP004 because of the extended patent protection it offers but also because it seems to offer significant potential improvements (less side effects?) to their existing marketed drug, so they could even increase their drugs market share.
Conversely the originator will not want a competitor to get hold of NXP004 as it will mean they lose a £billion a year drug market to a competitor who now has an improved form of their drug and who could then become the market leader.
FFS you say – ‘I also found it odd that he talked about the BD role in relation to NXP002 and not really NXP004. Does that mean that there is less work to do for NXP004 than there is for NXP002?’
My take is as follows:
With NXP002 they are talking about worldwide licensing, not just Asia, so they will presumably have to expend a reasonable amount of time and energy initially exploring who is interested worldwide and the different options on territories etc before they can get into more detailed negotiations with interested companies – it may include Kissei within that mix as a licensee (possibly joint or sole), or indeed may not.
Whereas with NXP004 they know who the originator is and they are obviously the first port of call, so it avoids completely the first phase of business development and all the associated legwork that is required for NXP002.
So, I believe you are correct, there is less work to do for NXP004 than there is for NXP002.
Whimax - you are right - I have just bought a load at 1.149p.
Proactive interview with Alastair Riddell - worth watching.
‘The monthly settlement amounts for the First Sharing Agreement are structured to commence approximately three months following Admission of the First Subscription Shares.’
So it will be mid-March 2022 before we get a first glimpse of what this deal means and is obviously dependent upon the sp at that time.
Hopefully business development progress with NXP004 will be evident by then to bolster the sp.
They now have all the ingredients in place to get a decent new CEO .
NXP004 patents and positive research plus further potential being investigated - and license discussions with originator.
NXP002 positive results - with additional studies proposed - leading to licensing discussions.
Additional funding now in place to see through the next 20 months.
They have made it relatively attractive for new CEO to come in, do the deals and reap the rewards.
I think we will see new CEO announced soon.
What a strong smell of panda s**t.
Agree Soup
As you say a pointless comparison to IMM.
Also should note that their Lanstead subscriptions were at a 25% discount to share price (for £2.66M) and a 6.5% discount to share price (for £1.3m).
Exactly SuperStockMan
Feels like we are dredging the very bottom of the barrel now to find things to be affronted about.
Hi Soup
You say that you ' find odd is that all of the board members, Riddell, Brindley, Gilbert and Kennedy regularly post news on their linkedin pages, but... none of them has ever posted anything about Nuformix, lots about the other companies they work for, but not NFX?'
I was intrigued and so went onto Linkedin expecting to see loads of posts for all our directors - I selected 'All activity' and found next to nothing posted in the last year from any of them. Where are you seeing all these regular posts you mentioned?
AB had just one post 6 months ago congratulating a professor at Imperial College and nothing else within a year.
JG also had just one post 2 moths ago about the Oxitope Pharma launch and nothing else within the year.
AR also had just one post 1 month ago about Ubiquitent's extended relationship with BMS and nothing else within the year.
I am puzzled regarding your comments? lots about their other companies??
In the same interview on 17th November AR stated:
"We will be upping our activities in the business development field"
Seems to suggest that having concentrated on the science they are now moving onto extracting the licensing potential and the deals.
Soup
AB stated in her Proactive interview of 17th Nov (at 4.17 minutes in).
"We plan to start to talk to potential licensees now we have filed this patent application"